KNSA - Kiniksa Pharmaceuticals to Present at Goldman Sachs 45th Annual Global Healthcare Conference

HAMILTON, Bermuda, June 04, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the Goldman Sachs 45 ^th Annual Global Healthcare Conference on Tuesday, June 11, 2024 at 8:40 a.m. Eastern Time.

A live webcast of Kiniksa’s presentation will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com . A replay of the event will also be available on Kiniksa’s website within approximately 48 hours after the event.

About Kiniksa
Kiniksa is a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa’s immune-modulating assets, ARCALYST ^® , abiprubart, and mavrilimumab, are based on strong biologic rationale or validated mechanisms, target a spectrum of underserved cardiovascular and autoimmune conditions, and offer the potential for differentiation. For more information, please visit www.kiniksa.com .

ARCALYST ^® is a registered trademark of Regeneron Pharmaceuticals, Inc.

Every Second Counts! ^®


Kiniksa Investor and Media Contact
Rachel Frank
(339) 970-9437
rfrank@kiniksa.com